COMPARISON OF STNFR55 IGG WITH ORAL METHOTREXATE IN ACTIVE RHEUMATOID ARTHRITIS

RO 45-2081是一种重组分子，由完整的 人55kD肿瘤坏死因子α受体胞外区和AN 免疫球蛋白重链序列。它的设计是为了拥有更长的 体内半衰期和比天然的更高的肿瘤坏死因子中和能力 肿瘤坏死因子抑制剂。以前的研究已经利用静脉输液治疗 患有类风湿性关节炎的患者，并已显示出良好的疗效。 目前的研究将利用皮下给药途径。 单独给药或与甲氨蝶呤联合给药，将评估 类风湿性关节炎的临床和功能表现 12周为一疗程。

Ro 45-2081 is a recombinent molecule that consists of the complete extracellular domain of the human 55 KD TNF alpha receptor and an immunoglobulin IgG heavy chain sequence. It is designed to have a longer in vivo half-life and higher TNF neutralizing capability than a natural TNF inhibitor. Previous studies have utilized intravenous infusion in patients with rheumatoid arthritis and have demonstrated salutory effects. The current study will utilize a subcutaneous route of administration either given alone or in combination with methotrexate and will evaluate the clinical and functional manifestations of rheumatoid arthritis over a 12 week period.